Dr Lin has written a large amount of articles including commentaries, hypothesis, registries analysis and meta-analysis with regard to clinical trials for cardiovascular medicine published in many worldwide renowned journals such as the JAMA, Annals of Internal Medicine, and Circulation. In addition, he was also invited to write a book chapter regarding atherosclerotic renovascular disease and attended to be a speaker discussing a controversy issue of pexelizumab for primary coronary revascularization in the international congress of cardiology held in Beijing in December, 2011. His major interest of research is widely related to clinical trials for cardiovascular disease, antiplatelet therapy for acute myocardial infarction, epidemiology, inflammation and metabolic syndrome.